Drug Information

Drug (ID: DG01839) and It's Reported Resistant Information

• Name: Astragaloside IV
• Synonyms: Astragaloside IV; 84687-43-4; Astragaloside A; Cyclosiversioside F; UNII-1J6XA9YCFV; 1J6XA9YCFV; CHEBI:65457; (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; 83207-58-3; (2R,3R,4S,5S,6R)-2-[[(1S,3R,8R,9S,11S,12S,14S,15R,16R)-14-Hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; 3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylcycloastragenol; C41H68O14; AS-IV; MFCD16036240; Cyclosieversioside F; AST-IV; Astragaloside IV 95%; Astragaloside IV, >98.0%; CHEMBL3121562; SCHEMBL21888259; HMS3885E12; HY-N0431; s3901; AKOS025311424; ZINC238809356; CCG-270470; AS-19402; beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl; K514; X7614; C17799; 846A434; Q27133900; Astragaloside IV, European Pharmacopoeia (EP) Reference Standard; Astragaloside IV, United States Pharmacopeia (USP) Reference Standard; (2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Idiopathic interstitial pneumonitis [ICD-11: CB03]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 7
• IsoSMILES: C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O
• InChI: InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/m0/s1
• InChIKey: QMNWISYXSJWHRY-YLNUDOOFSA-N
• PubChem CID: 13943297

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-12: Respiratory system diseases

Idiopathic interstitial pneumonitis [ICD-11: CB03]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: SIRT1 antisense RNA (SIRT1-AS) [1]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Pulmonary fibrosis [ICD-11: CB03.1]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: RLE-6TN cells; Lung; Rattus norvegicus (Rat); CVCL_4693
• Experiment for Molecule Alteration: Overexpression assay; Knockdown assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: Collectively, sirt1 AS was critical for ASV-mediated inhibition of IPF progression and targeting of sirt1 AS by ASV could be a potential therapeutic approach for IPF.

References

• Ref 1: Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transitionAging (Albany NY). 2020 Mar 6;12(5):4322-4336. doi: 10.18632/aging.102882. Epub 2020 Mar 6.